These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 26279055)
1. Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients. Thom C Future Oncol; 2015 Sep; 11(18):2499-501. PubMed ID: 26279055 [TBL] [Abstract][Full Text] [Related]
2. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360 [TBL] [Abstract][Full Text] [Related]
3. ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. Gorcea CM; Burthem J; Tholouli E Future Oncol; 2018 Aug; 14(20):1995-2004. PubMed ID: 29498296 [TBL] [Abstract][Full Text] [Related]
4. Closing in on targeted therapy for acute myeloid leukaemia. The Lancet Haematology Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709 [No Abstract] [Full Text] [Related]
5. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study. Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554 [TBL] [Abstract][Full Text] [Related]
6. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in Dumas PY; Villacreces A; Guitart AV; El-Habhab A; Massara L; Mansier O; Bidet A; Martineau D; Fernandez S; Leguay T; Pigneux A; Vigon I; Pasquet JM; Desplat V Clin Cancer Res; 2021 Nov; 27(21):6012-6025. PubMed ID: 34400415 [TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776 [TBL] [Abstract][Full Text] [Related]
8. Availability of FLT3 inhibitors: how do we use them? Perl AE Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254 [TBL] [Abstract][Full Text] [Related]
10. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841 [TBL] [Abstract][Full Text] [Related]
11. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Weis TM; Marini BL; Bixby DL; Perissinotti AJ Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288 [TBL] [Abstract][Full Text] [Related]
12. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130 [TBL] [Abstract][Full Text] [Related]